




From the CEO's Desk

The past several months have marked an important transition for Perimeter to achieving a significant regulatory milestone to executing on our commercial strategy.



Adrian Mendes, CEO

We announced Intermountain Health as the first health system in the U.S. to commercially deploy Claire. This installation represents the beginning of what we believe will be a broader shift toward AI-enabled intraoperative imaging in breast-conserving surgery. We continue to see encouraging engagement from healthcare providers who recognize Claire's ability to improve surgical decision-making and help reduce the likelihood of repeat procedures.

During the second quarter of 2026, we further strengthened our financial position through a successful financing that included both existing shareholders and new healthcare-focused institutional investors. This financing significantly strengthens our balance sheet and positions us to execute the U.S. commercial launch of Claire. Perimeter was also one of 10 companies selected for funding in the latest round of the INOVAIT Pilot Fund, a program supported by the Government of Canada. INOVAIT provides non-dilutive funding for commercialization-focused R&D projects involving the integration of artificial intelligence (AI) into integrated image-guided therapy.

Looking ahead, our priorities remain focused on disciplined execution:

1. Accelerating Adoption: Expand Claire installations across leading breast cancer centers and convert our growing pipeline into long-term customer relationships.
2. Generating Clinical Momentum: Build real-world evidence that reinforces Claire's value for surgeons, patients, and health systems.
3. Advancing Our Platform: Leverage our proprietary AI-enabled OCT technology to pursue additional clinical applications beyond breast-conserving surgery.

The progress we've made reflects the dedication of our team, the confidence of our clinical partners, and the ongoing support of our shareholders. We are excited by the opportunities ahead and believe Perimeter is entering an important new phase of growth.

Thank you for your continued support.

What Investors Should Know

[Intermountain Health Brings Perimeter's Claire™ to the Operating Room, a Landmark in Breast Cancer Surgery Using AI](#)

Intermountain Health, the largest nonprofit health system in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter's Claire OCT System™, the only FDA-approved imaging device that uses AI during breast cancer surgery to help surgeons see microscopic tissue structures - where cancer can be difficult to detect - in real-time, for margin assessment.

[Perimeter Announces Preliminary Second Quarter 2026 Financial Results](#)

- Perimeter achieved the first two commercial placements of the Claire device – consisting of legacy replacements of Perimeter S-Series systems by two top-tier hospitals
- Revenue was approximately \$503,000 for the second quarter of 2026, with the full amount coming from recurring revenue
- Operating expenses for Q2, 2026 were approximately \$3.1 million, down 28% from \$4.3 million in the same period in 2025.

[Perimeter Medical Imaging AI Closes Life Offering](#)

Perimeter is pleased to announce the successful closing of its previously announced "best efforts" offering, pursuant to the listed issuer financing exemption, of 19,533,500 units of the Company at a price of \$0.35 per Unit for aggregate gross proceeds of approximately C\$6,836,725. The Company expects to issue an additional 1,955,500 Units, for additional gross proceeds of C\$684,425, in a final tranche of the Life Offering on or about May 6, 2026, to bring the total offering up to the maximum offering size of 21,489,000 Units (C\$7,521,150).

Other Press Highlights

[Perimeter Selected for INOVAIT Pilot Fund to Advance AI for Breast Cancer Surgery](#)

Perimeter has been selected to receive a contribution from the [INOVAIT Pilot Fund](#) to advance next-generation AI capabilities for its flagship product Claire™, the first AI-enabled imaging device for use during breast cancer surgery. The project was one of 10 selected for funding in the latest round of the INOVAIT Pilot Fund call for applications.


What Customers Are Saying at Intermountain Health, UT

"Every breast surgeon wants to give their patient the best possible chance of completing treatment in a single surgery, but microscopic cancer can be difficult to identify in the operating room, Claire was incredibly simple to incorporate into my workflow. The AI quickly directed my attention to specific areas of concern, giving me an additional set of trained eyes and more information to guide my decisions during these procedures."



Dr. Teresa Reading
Breast Surgeon,
LDS Hospital

"Claire AI is a great adjunct to margin assessment intraoperatively for breast cancer. Scanning is very quick. I'm looking forward to more cases and postoperative Pathology input. The Perimeter team has been a great support through this transition!"



Dr. Jennifer Tittensor
Breast Surgeon,
American Fork Hospital

Market Visibility & Impact Events



[Intermountain's Adoption of Claire in Imaging Technology News](#)



[Intermountain's Adoption of Claire in BriefGlance](#)



[Perimeter Medical Imaging CEO, Adrian Mendes discusses OCT with TechEdge AI](#)




[Claire vs. the Competition: How Perimeter's Device Stacks Up Against a New Rival and the Old Standby](#)



[Perimeter Medical Imaging AI on FDA Clearance, AI-Assisted Surgery and 2026 Catalysts](#)




[Perimeter Medical Imaging AI CEO Adrian Mendes presents at Planet MicroCap](#)



[Perimeter Medical Imaging AI won the TAG Awards in the MedTech category for the second time in a row!](#)




[Perimeter returned to ASBrS with a major milestone achieved: the launch of Claire](#)



[Perimeter Medical Imaging AI CEO Adrian Mendes presents at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto](#)

Inside Perimeter: People & Partnerships Driving Our Mission



LEADERSHIP SPOTLIGHT

Abbey Goodman

Vice President, Sales
Perimeter Medical Imaging AI

1. What are the biggest challenges facing healthcare providers today, and how is Perimeter uniquely positioned to offer a unique solution? Healthcare providers and systems are under constant pressure to improve patient outcomes while managing costs and operational complexity.

That's exactly where Claire fits. During a lumpectomy, Claire gives surgeons real-time, 3D visualization of tissue margins while the patient is still on the table. Claire is adjunctive, working alongside the pathology process to give surgeons more information earlier, potentially reducing the likelihood of a re-operation due to positive margins.

What differentiates Perimeter commercially is our dual-path strategy: we engage surgeons on clinical evidence and workflow, while also empowering patients to ask for Claire by name. The value story is clear: better intraoperative information, potentially fewer re-operations, and a meaningfully improved experience for the patient. That's the ROI conversation I'm having with health systems.

2. What qualities or capabilities do you believe are most essential for Perimeter as we move through this next stage of growth? Several capabilities are essential, but we need to maintain adaptability with a growth mindset. So our ability to build strong relationships from securing marquee partnerships across hospital organizations, IDNs, and building the brand through new physician partners is going to be critical to our success. Strong leadership across the organization is also very critical. We continue cultivating a top calibre team and aligning internal stakeholders from marketing, R&D, engineering with customer insights obtained in the field to make an impact.

Industry News

[Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform](#)

Abbott recently secured both FDA 510(k) clearance and a CE mark for its Ultreon 3.0 platform, which integrates artificial intelligence with artificial coherence tomography (OCT) to give interventional cardiologists faster, high-resolution insights during critical procedures.

[AI-Powered Medical Devices: Funding & Acquisition Landscape in 2026](#)

The era of AI as a "nice-to-have" bolt-on for medical device companies is over. In 2025-2026, artificial intelligence has become the single most important driver of medtech deal flow, venture funding, and strategic M&A.

What's Next

September 29, 2026

Unlocking AI in Oncology Panel Discussion

Register [here](#)

- Hosted by Translational Research and Applied Medicine, Stanford Medicine
- September 29 - 5:30 - 8:00 pm PT - Palo Alto
- Meet the Panelists:

1. AI meets Oncology, from Hype to Impact

Janice Lu, MD, PhD

Clinical Professor (Oncology) and Director of AI (TRAM), Stanford Medicine

2. AI & Oncology Addition

Dean Felsner, MD, PhD

Professor of Medicine-Oncology and (Pathology), and Director of Stanford TRAM Center, Stanford Medicine

3. How AI helps surgeons make real-time decisions in the OR

Adrian Mendes

CEO of Perimeter Medical and ex-COO of Groq

4. How universities, research institutions, and pharma partners can bring verified, high-integrity data into the AI development pipeline

Michael McLaughlin, JD

CEO of VeridatAI, ex-Sr. Advisor, U.S. Cyber Command and the National Security Agency

Quick Links

Investor Deck

SEDAR+ Files

News Room

Leadership Bios

Contact Investor Relations

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

This information is intended for an investor audience and not for use by healthcare professionals. The information contained herein should not be used to guide clinical practice.

S-Series OCT


The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

For full information on unapproved/off-label uses, visit: [perimetermed.com/disclosures](#) or contact medicalaffairs@perimetermed.com.

Claire OCT System

The Perimeter Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. Claire is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.


You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the "Unsubscribe Preferences" link below if you wish to opt out of this e-newsletter.



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

TSXV: PINK | OTC: PYNKE | ESE: 4PC



© 2026 Perimeter Medical Imaging AI, Inc.